On April 29th, the Commendation Conference for Model Workers, Advanced Workers and Model collectives in Beijing was grandly held at Beijing Conference Center. Approved by the Beijing Municipal Committee of the Communist Party of China and the Beijing Municipal People's Government, the antibody drug research and development team of Beijing Sungen Biomedical Technology Co., Ltd. was awarded the honorary title of "Model Collective of Beijing".
Since its establishment, the antibody drug research and development team of Sungen Biomedical, led by Professor Sun Zhiwei, has been responsible for the mission of "Innovation leads the future and benefits human health". The team always regards scientific and technological innovation as the core driving force for development and continuously explores in the field of original antibody drug research. The team has successfully established a series of international advanced technology platforms, actively expands the R&D pipeline covering multiple fields such as cardiovascular and cerebrovascular diseases, tumors, neurodegenerative diseases, and autoimmune diseases, constantly explores new therapeutic targets and drug mechanisms of action, and continuously strives to address more unmet clinical needs, pursuing excellence. The technological innovation capabilities they have demonstrated not only represent a breakthrough in traditional R&D model but also inject new impetus into the development of the biopharmaceutical industry. The SGC001 injection, the world's first AMI antibody drug developed by the team, is currently undergoing Phase Ib clinical trials in multiple centers across the country.
From technological breakthroughs to industrial empowerment, from protecting lives to serving the society, the practices of the antibody drug R&D team of Sungen Biomedical are interpretation of the model worker spirit of the new era in the field of scientific and technological innovation. This recognition as a "Model Collective of Beijing" is a full affirmation by the Beijing Municipal Committee of the Communist Party of China and the Beijing Municipal Government to Sungen Biomedical R&D team as "serving the country through science and strengthening the country through industry". This honor is also an encouragement. In the future, Sungen Biomedical will continue to be patient-oriented, scale the heights of science and technology, overcome more technical difficulties, inject new impetus into the high-quality development of the capital's biopharmaceutical industry, and promote Chinese innovative drugs to the world.
Li Jing, Deputy General Manager of Sungen Biomedical, accepted the recognition on behalf of the team
Updated: May 05, 2025
